

GP 1654  
\$  
Patent  
224/042

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Andrew Young et al.

Serial No.: 08/851,965

Filed: May 6, 1997

For: **METHOD FOR PREVENTING  
GASTRITIS USING AMYLIN OR  
AMYLIN AGONISTS**

Group Art Unit: 1654

Examiner: Celsa, B.

RECEIVED

AUG 0 6 1999

TECH CENTER 1600/2900

#13  
5-10-00

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the Applicants' duty under 37 CFR 1.97-98, the following information is brought to the attention of the Examiner. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner. However, Applicants have not provided copies of the listed books, due to their bulk. Please advise if copies of these items are needed.

SD-119191.1

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

July 30, 1999

Date of Deposit

Karen M. Cruz

Name of Person Mailing Paper

Signature of Person Mailing Paper

00000032 08851965

19/05/1999 TLW11

240.00 DP


The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 CFR 1.56 and the submission thereof by Applicants shall not be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR 1.97(h)), or even qualifies as "prior art" under 35 U.S.C. § 102 with respect to this invention unless specifically designated by Applicants as such.

The filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR 1.56, exists.

This Information Disclosure Statement is being filed in accordance with 37 CFR §§1.97(c) and 1.98. This IDS is being filed after an action on the merits but before a Final Action under §1.113 or a Notice of Allowance under §1.311. Enclosed is a check in the amount of \$240.00 to cover the fee pursuant to 37 CFR §1.17(p). The Examiner is hereby authorized to charge any additional fee required by this paper to Lyon & Lyon's Deposit Account No. **12-2475**.

Respectfully submitted,

LYON & LYON LLP

By:   
Charles S. Berkman  
Reg. No. 38,077

633 West Fifth Street, Suite 4700  
Los Angeles, California 90071-2066  
(858) 552-8400